PLDALPHA2 Antibody
Description
Antibody Structure and Functional Context
Antibodies targeting phospholipase-related proteins typically exhibit immunoglobulin G (IgG) structures, comprising two heavy (H) and two light (L) chains with antigen-binding Fab regions and an Fc domain mediating effector functions . Key antibody classes include:
| Antibody Class | Heavy Chain | Molecular Weight (kDa) | % Serum Ab | Functional Role |
|---|---|---|---|---|
| IgG | γ (gamma) | 150 | 80 | Neutralization, opsonization |
| IgM | μ (mu) | 900 | 6 | Early immune response |
| IgA | α (alpha) | 385 | 13 | Mucosal immunity |
Data adapted from Bio-Techne .
PLA2G7/PAF-AH/Lp-PLA2 Antibody
PLA2G7 (Lipoprotein-associated phospholipase A2) antibodies are critical in cardiovascular research. This enzyme hydrolyzes oxidized phospholipids in LDL and HDL, generating pro-inflammatory mediators . Key properties:
-
Function: Hydrolyzes platelet-activating factor (PAF) and oxidized phospholipids, linked to atherosclerosis .
-
Assays: Detected via Western blot (~29–33 kDa) and ELISA with high specificity .
PLBL2 Antibody in Therapeutic Development
Phospholipase B-like 2 (PLBL2) is a host-cell protein (HCP) impurity in monoclonal antibodies (mAbs) produced in Chinese hamster ovary (CHO) cells .
Key Research Findings:
-
Immune Response: ~90% of subjects in clinical trials developed anti-PLBL2 antibodies, though no correlation with adverse events was observed .
-
Assay Challenges: PLBL2 causes nonlinear dilution in ELISA due to antigen excess (Figure 4) .
-
Purification Impact: Process optimization reduced PLBL2 levels to <1 ng/mg in final mAb products .
| Parameter | PLBL2 in mAb Production |
|---|---|
| Initial PLBL2 levels | Up to 300 ng/mg |
| Post-purification levels | <1 ng/mg |
| Assay recovery (low PLBL2) | ~100% |
| Assay recovery (high PLBL2) | Nonlinear (antigen excess) |
Data from Bioprocess International .
Clinical Relevance of Phospholipase Antibodies
-
Thrombosis Risk: High-risk antiphospholipid antibody profiles (e.g., LA-positive or aCL/aβ2GPI ≥40U) correlate with persistent positivity and thrombosis in 28% of pediatric patients .
-
Diagnostic Tools: Recombinant Plasmodium lactate dehydrogenase (pLDH) antibodies (e.g., mAb 2CF5) show species-specific detection limits of 31.3 ng/mL .
Analytical and Therapeutic Challenges
-
Fc Engineering: Mutations like LALA-PG (L234A/L235A/P329G) eliminate FcγR binding, reducing effector functions in therapeutic antibodies .
-
Host-Cell Protein Risks: PLBL2 copurifies with mAbs via Fab interactions, necessitating stringent process controls .
Emerging Tools and Databases
Product Specs
Target Background
KEGG: ath:AT1G52570
STRING: 3702.AT1G52570.1
Q&A
Here’s a structured FAQ collection for researchers focusing on PLDALPHA2 (phospholipase D2, PLD2) antibody applications in academic research, synthesized from peer-reviewed studies and technical reports:
Advanced Research Questions
How can PLD2 antibody reactivity patterns resolve functional isoforms?
-
Approach:
-
Employ 2D gel electrophoresis followed by Western blot to separate phosphorylated/non-phosphorylated isoforms .
-
Combine with LC-MS/MS to map antibody-binding regions to specific domains (e.g., PX/PH domains) .
-
Example finding: Anti-PLD2 antibody 12116-1-AP detects full-length PLD2 (106 kDa) but not truncated variants .
-
What computational tools enhance PLD2 epitope characterization?
-
Integrated Workflow:
How do I reconcile PLD2’s dual roles in cancer progression?
-
Contradiction Analysis:
| Study Type | Reported Role | Contextual Factors |
|---|---|---|
| Colorectal cancer | Tumor-suppressive | Associated with EMT inhibition |
| Breast cancer | Oncogenic | Linked to mTOR pathway activation |
-
Resolution: Conduct conditional knockout models with tissue-specific promoters to assess microenvironment-dependent effects.
Technical Validation
What orthogonal methods confirm PLD2 antibody specificity?
-
Multi-Modal Validation:
Data Integration
How to harmonize PLD2 data across omics platforms?
-
Framework:
